March 9, 2020 / 2:20 PM / 22 days ago

BRIEF-Shanghai Henlius Biotech Says Clinical Trial Application For Co's Recombinant Anti-Rankl Human Monoclonal Antibody Injection Accepted By NMPA

March 9 (Reuters) - Shanghai Henlius Biotech Inc:

* CLINICAL TRIAL APPLICATION FOR CO’S RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION ACCEPTED BY NMPA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below